Latest Breaking News On - Sam slutsky - Page 1 : comparemela.com

CG Oncology Reports Bladder Cancer Treatment - Orange County Business Journal

Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript

Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode.

LifeSci Capital Reaffirms Their Buy Rating on Immunovant (IMVT)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $34.00..

LifeSci Capital Reaffirms Their Hold Rating on Rain Therapeutics (RAIN)

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Rain Therapeutics (RAIN – Research Report). The c.

Mizuho Securities Keeps Their Buy Rating on Rain Therapeutics (RAIN)

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Rain Therapeutics (RAIN – Research Report).